Soar BioDynamics, Ltd. Unveils New Dynamic Screening Tool
SAN FRANCISCO – (March 25, 2009) Soar BioDynamics, Ltd., a pioneer in Webbased personalized data-driven health analysis, today announced the debut of its highly anticipated first product, Soar Dynamic Screening for the prostate.
Developed in conjunction with some of the world’s leading researchers in urology, Soar Dynamic Screening demonstrates a new approach to healthcare by providing men a detailed analysis of their prostate health based on several factors beyond the industry-standard Prostate-Specific Antigen (PSA) test. Because the PSA test is controversial as a stand-alone tool, Soar Dynamic Screening also analyzes other important variables including a man’s personal health history, PSA trends over time and comparisons with up to a million case studies. Soar Dynamic Screening is available now at www.soarbiodynamics.com.
"Monitoring prostate health over time is more powerful and precise than single screening visits," said Dr. Christopher J. Kane M.D., Professor of Surgery and Chief of Urology, University of California San Diego. "Soar BioDynamics should help physicians and patients decide when additional diagnostic tests for prostate cancer may be useful."
Soar BioDynamics’ team comprises the best and the brightest in the medical, engineering and technology fields. Leading voices in urology have joined the company's Scientific Advisory Board, assuring that Soar Dynamic Screening for the prostate reflects the trends and advances in the field. Members of Soar BioDynamics’ Scientific Advisory Board include Dr. Christopher J. Kane M.D. and Dr. Georg Bartsch, M.D., Professor and Chair of the Department of Urology at Innsbruck Medical University. Announcements of additional prominent members of the advisory board are expected soon.
"As recent studies have again proven, one PSA test does not deliver enough information," said Dr. Georg Bartsch, M.D. "It is vitally important to monitor indicators over time and provide men with personalized analysis of their prostate health."
Soar Dynamic Screening for the prostate uses individual profile data, test results and cutting-edge technology to deliver personalized analysis. Through an easy-to-use Web-based tool, men enter the results of their PSA test history and personal information such as height, weight and health history. This information is compared with up to a million case studies and outcomes from other men with various prostate conditions. Finally, the system may suggest a medical detective process for doctors and their patients in their efforts to detect non-cancerous prostate conditions and improve prostate cancer screening. Soar provides men with 20 opportunities annually to analyze their prostate health data, enabling ongoing, up-to-date analysis when needed to support men and their doctors’ efforts to conduct medical detective processes. Soar does not collect personally identifiable information, maximizing patient privacy.
"When I received my prostate cancer diagnosis, it felt like a death sentence," said Tom Neville, CEO, chief scientist and founder of Soar BioDynamics. "There were no clear answers to the questions I had surrounding my health, and I was confronted with irrevocable procedures that might have been unwarranted. I founded Soar because I did not want any other man to go through such a life-altering process without being armed with personalized information and analysis to help make decisions."
For more information regarding Soar BioDynamics, Ltd. or to view a sample report, please visit http://www.soarbiodynamics.com.